All News
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA
A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).
Predictors of Adverse Pregnancy Outcomes in Lupus
A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before and at concept
Anxiety and Depression Rising in Rheumatoid Arthritis
A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
Pain Relief in RA: JAK Better than TNF Inhibitors?
d
MedPage Today
Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.
Read Article
Anxiety and Depression Rising in Rheumatoid Arthritis
A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
https://t.co/sWawAgDgyS https://t.co/dVTb7QMFNj
Dr. John Cush RheumNow ( View Tweet)
#VEXAS can present as atypical &/or refractory #ANCA-associated #vasculitis
Consider possibility of VEXAS in cases of AAV
▶️Refractory to multiple treatment
▶️Atypical kidney biopsy
👉🏽https://t.co/1Vewb5n5vZ
via @RheumJnl https://t.co/FLov5xaQAA
Links:
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Biomarker substudy of #SLE Rx w/ low dose IL-2 Rx in 342 pts (40% responders). SRI-4 predicted by rash, proteinuria, uRBC, %CD4 T cells, C3 (AUC 0.9330; however renal markers did not correlate with achieving LLDAS. https://t.co/pDgwegbU6t https://t.co/72w4gNAiWt
Dr. John Cush RheumNow ( View Tweet)
In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar. https://t.co/QVbEVvYz7y https://t.co/1Te22NIUGT
Dr. John Cush RheumNow ( View Tweet)
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/cH4s99Fzka https://t.co/kNcUqahmeS
Dr. John Cush RheumNow ( View Tweet)
Retrospective population study of 383 #AS women who were pregnant (3.8/100,000) compared to controls. AS-Preg pts more likely to be older; White, w/ higher incomes, MORE thyroid Dz, Pregs, C-Sections, gestational DM, placenta previa, more neonatal SGA, IUFD… https://t.co/pgsmKgljwx https://t.co/IMJ8CTrqhY
Dr. John Cush RheumNow ( View Tweet)
Study of AutoAbs in 141 pts w/ systemic sclerosis overlap syndrome (SSc OS). Most common Abs: Ro-52, centromere (ACA) & anti-Scl-70. Scl-70 was assoc w/ ILD & SSc renal crisis (SRC); while ACA is protective factor of ILD. SRC & pulm HTN assoc w/ incr mortality… https://t.co/sqQhIlZjdB https://t.co/noyaFbd3Z8
Dr. John Cush RheumNow ( View Tweet)
US health expenditures grew from $4.1 trillion in 2020 to $4.5 trillion in 2022 (17.3% incr).
US saved >$400 billion in 2022 by using generic and biosimilar drugs, https://t.co/Z8kS4elyA3 https://t.co/3LopIiQiqZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Claims study presented at SASM mtg by HSS orthopedists found among >100k Hip/Knee replacement surgeries, the 19% who used CPAP (OSA) had significantly fewer ER visits and postop complications. https://t.co/kg7oCRndqH https://t.co/WRcxUD3c6V
Dr. John Cush RheumNow ( View Tweet)
Dr. Lindsey Criswell Elected to National Academy of Medicine. Dr. Criswell is the NIAMS Director and is known for her research in SLE, RA, and Sjogrens. Congrats!! https://t.co/3l4VHqnH2m https://t.co/FDcNVGjw4l
Dr. John Cush RheumNow ( View Tweet)
Manual labor jobs have more work disability in #PsA. 564 PsA pts, 29% were Blue collar; 71% White Collar. BCol (80% male) had more work disability at baseline (84% vs 28%; p < 0.01). Occupation did not influence DAS28-CRP remission at 1 yr, suggesting Rx response unaffected by… https://t.co/A9E5WZqIwu https://t.co/8PelrtpXco
Dr. John Cush RheumNow ( View Tweet)
Impact of biosimilars on biologic drug development pipelines. https://t.co/7kc0UDVPTy https://t.co/bPV3wAc2XY
Dr. John Cush RheumNow ( View Tweet)
Turkish retrospective review of 30 axSpA/PsA pts w/ Hx of prior malignancy and went on Rx w/ secukinumab betw 2018-2024. After mean F/U of ~ 30mo, SEC retention was 90% @12 mos & 81% @24 mos. There was only 1 local tumor recurrence w bladder carcinoma https://t.co/t7tqPtHOff https://t.co/wfAxwEsZLK
Dr. John Cush RheumNow ( View Tweet)
Alendronate Atypical Fractures Back In Court
Reuters reports that a U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck failed to warn that patients taking alendronate for osteoporosis may be at increased the risk of atypical femoral fractures.… https://t.co/DWXsFyzfWs https://t.co/HhROUArYBE
Dr. John Cush RheumNow ( View Tweet)
Economic and Mental Health Burden of Rheumatoid Arthritis
A University of Mississippi-led comprehensive study of a disorder that affects 4.27 million Americans nationwide is revealing just how significant its burdens are on patients' financial well-being and quality of life.… https://t.co/UpxHJSG6BL https://t.co/luPp1gjlRA
Dr. John Cush RheumNow ( View Tweet)